2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2640

Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2161

Hemophagocytic Syndrome in Adults and Association with Rheumatologic Diagnoses: US National Inpatient Trend over Nine Years

Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1995

Heparan Sulfates from Human Osteoarthritic Cartilage Display Increased Sulfation Pattern, Decrease the Protein Binding Capacity to FGF-2 and Increase the Binding to VEGF and Induce Changes of Human Mesenchymal Stem Cell Behavior

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 2767

Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2451

Herpes Zoster in Rheumatoid Arthritis. Prospective Single Center Study of 390 RA Patients for 5 YEARS

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: L08

High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response

Late-Breaking Abstract Poster Session

9:00AM-11:00AM: Abstract Number: 2273

High Dose Intravenous Methylorednisolone Induces Rapid Improvement in Severe Non-Infectious Uveitis. a Multicenter Study of 120 Patients

Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

9:00AM-11:00AM: Abstract Number: 2692

High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2778

High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2333

High Serum Uric Acid Protects Against Osteoporosis in Postmenopausal Women: Data from the Korean National Health and Nutrition Examination Survey

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2761

High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2240

Hip Involvement in Patients with Gout: Results of an Ultrasound Study

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1962

HLA Contributions to Risk and Protection for Anti-Centromere Autoantibody-Positive Scleroderma

Genetics, Genomics and Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2373

How Do Patients Describe Their “New Normal” in Systemic Lupus Erythematosus? Use of Probabilistic Topic Modelling to Characterize Patients’ Experiences Recorded in an Online Health Community

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2088

Human TLR8 at the Interface between Innate and Adaptive Immunity in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Animal Models Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].